Prospective randomized, group-controlled pilot study 2021-2022 of clinical causality, efficacy and safety of the CE-marked app "mediteo m+"

Prospective randomized, group-controlled pilot study 2021-2022 of clinical causality, efficacy and safety of the CE-marked app "mediteo m+" - mediteo 2021-2022

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00026278

Enrollment

Registered

2023-07-24

Start date

2022-02-11

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Adherence

Interventions

Group 1: mediteo +1 app Group 2: TAU, Therapy as usual

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Chronic medication

Exclusion criteria

Exclusion criteria: Serious internal, neurological, vision disease

Design outcomes

Primary

Measure	Time frame
Actual tablet count divided by target tablet count	—

Secondary

Measure	Time frame
Blood pressure	—

Countries

Germany

Contacts

Public ContactHans-Peter Zenner

Clinical Research OrganizationHP Zenner Clinical GmbH&CoKG

office@hpzenner.de+49707149645

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026